ABL Bio

에이비엘바이오 · 298380

Health Care Pharmaceuticals · KOSDAQ

Large-cap

Market cap US$4.3B (₩6T)

Overview

Company summary coming soon.

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$57.5M

▲ +137.6% YoY

Operating profit · FY2025

−US$29.3M

Loss narrowed

Net income · FY2025

−US$27.4M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$47.5M(₩65.5B)	US$24.2M(₩33.4B)	US$57.5M(₩79.3B)
Operating profit	−US$1.9M(−₩2.6B)	−US$43M(−₩59.4B)	−US$29.3M(−₩40.4B)
Net income	−US$1.9M(−₩2.6B)	−US$40.2M(−₩55.5B)	−US$27.4M(−₩37.9B)

Revenue

Operating profit

Net income

ROE

-24.2%

Debt/Eq

79.3%

Op. margin

-50.9%

Net margin

-47.7%

Rev. YoY

▲ +137.6%

Interactive price history isn't here yet. Would you use it?